Generic Name: mitoxantrone (mye toe ZAN trone)
Brand Name: Novantrone
Company: Immunex
FDA Approved: October 2000
The recommended dosage of NOVANTRONE is 12 mg/m2 given as a short (approximately 5 to 15 minutes) intravenous infusion every 3 months.
Specific Treatments: Reduction of neurologic disability and/or the frequency of clinical relapses in patients with multiple sclerosis.
Novantrone has been approved for use in reducing neurologic disability and/or the frequency of relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Novantrone is not indicated for the treatment of patients with primary progressive multiple sclerosis.
White blood cells can produce the symptoms of multiple sclerosis by attacking myelin, a fatty substance that surrounds nerve cells. Novantrone suppresses the activity of T and B cells, and in this manner slows the progression of the disease and reduces the frequency of relapses.
No comments:
Post a Comment